Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
This research study is looking to see whether the combination of Dostarlimab and Niraparib
plus Radiation Therapy (RT) is safe and effective in participants with metastatic triple
negative breast cancer.
The names of the study treatment involved in this study are:
- Dostarlimab
- Niraparib
- Radiation Therapy (RT), which is given per standard of care.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Johns Hopkins University University of North Carolina University of Pennsylvania